Novo-boss after Ozempic's lightening growth: "There is still huge unfulfilled potential in GLP-1"
Novo Nordisk CEO Lars Fruergaard Jørgensen is "very satisfied" with the company's sale of its GLP-1 agonist Ozempic after seven quarters on the market. But he also believes that the company must make the market for the drug even bigger.
BY KEVIN GRØNNEMANN
On Friday morning, analysts around the world had to admit once again that their predictions for how quickly Novo Nordisk's diabetes treatment Ozempic could grow were too low.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Ozempic sells twice as fast as Victoza and Trulicity
For abonnenter
